ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

BACKGROUND & AIMS Ribavirin-induced anemia is one of the major causes of discontinuation and dose reduction during anti-hepatitis C virus therapy. Factors influencing this anemia, especially host genetic factors, are poorly understood. In this study we investigated predictive factors in hepatitis C virus patients treated with combination therapy. METHODS We performed a 2-step genome-wide screening followed by replication analysis and fine-mapping using a total of 923 Japanese hepatitis C virus 1b-infected patients treated with pegylated-interferon plus ribavirin. We also applied logistic regression analysis to search for possible independent associations of clinical parameters and genetic variants with treatment-induced hemoglobin (Hb) decline as well as treatment outcomes. RESULTS We identified a variant, located upstream of the inosine triphosphate pyrophosphatase gene on chromosome 20p13 that is significantly associated with treatment-induced anemia (combined P = 6.0 × 10(-14)). Resequencing and fine-mapping revealed several single nucleotide polymorphisms (SNPs) strongly associated with Hb decline, including the nonsynonymous SNP rs1127354 (P = 3.5 × 10(-44)), which was recently reported for other ethnic groups. Another reported SNP, the splicing variant-related SNP rs7270101, was not polymorphic in the Japanese population. Stratified analysis based on rs1127354 genotype revealed that inosine triphosphate pyrophosphatase expression is not correlated with Hb decline, suggesting that rs1127354 is a direct causal variant in the Japanese population. Multivariate analysis demonstrated that age, baseline Hb, baseline platelet count, and rs1127354 were independently associated with severe anemia (Hb <10 g/dL). CONCLUSIONS A missense substitution in inosine triphosphate pyrophosphatase gene affects ribavirin-induced anemia in hepatitis C virus-infected Japanese patients.

[1]  Jacques Fellay,et al.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.

[2]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[3]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[4]  Yoshiyuki Suzuki,et al.  Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.

[5]  H. Tajiri,et al.  Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment , 2009, Journal of Gastroenterology.

[6]  V. Armstrong,et al.  Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. , 2005, Clinical chemistry.

[7]  E. Kuipers,et al.  ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. , 2005, Gut.

[8]  H. Nomura,et al.  Factors contributing to ribavirin‐induced anemia , 2004, Journal of gastroenterology and hepatology.

[9]  R. Gearry,et al.  Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. , 2004, Pharmacogenetics.

[10]  Yoshiyuki Suzuki,et al.  Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C , 2004, Journal of Gastroenterology.

[11]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[12]  A. Bruchfeld,et al.  Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin‐induced anaemia , 2004, Journal of viral hepatitis.

[13]  Yusuke Nakamura,et al.  Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis , 2003, Nature Genetics.

[14]  R. Hegele,et al.  DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency , 2002, Journal of Human Genetics.

[15]  J. Sanderson,et al.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency , 2002, Human Genetics.

[16]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[17]  M. Manns,et al.  Peginterferon alfa-2b plus ribavirin for chronic hepatitis , 2002, The Lancet.

[18]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[19]  Yusuke Nakamura,et al.  A high-throughput SNP typing system for genome-wide association studies , 2001, Journal of Human Genetics.

[20]  M. Vos,et al.  Factors influencing ribavirin-induced hemolysis. , 2001, Journal of hepatology.

[21]  G. Fattovich,et al.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage , 2000, Hepatology.

[22]  C. Gil,et al.  Persistent hepatitis C viremia after acute self‐limiting posttransfusion hepatitis C , 1995, Hepatology.

[23]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[24]  B. S. Vanderheiden.  Genetic studies of human erythrocyte inosine triphosphatase , 1969, Biochemical Genetics.

[25]  J. Sanderson,et al.  The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. , 2007, Biochimica et biophysica acta.

[26]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .